Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

20.01 +0.13 (+0.65%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street
Wall Street is uber-bullish on these two Ark Invest holdings. 
Via The Motley Fool
CRISPR Therapeutics sets sights on gene-editing cures for disease
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for 
Via MarketBeat
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
From Beam Therapeutics
Via GlobeNewswire
Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Is Beam Therapeutics Stock a Buy Now?
It has plenty of money, but it'll be facing plenty of competition, too. 
Via The Motley Fool
Beam Therapeutics: Q3 Earnings Insights
Via Benzinga
Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble?
Beam Therapeutics' pipeline will look slimmer going forward. 
Via The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception
The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014. 
Via Benzinga
Topics ETFs
The 3 Best Gene Editing Stocks on the Frontier of Medicine
Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December. 
Via InvestorPlace
3 Monster Stocks in the Making
These stocks could grow much larger over the next few years. 
Via The Motley Fool
Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks
You might not get a better chance to invest in these disruptive companies. 
Via The Motley Fool
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results. 
Via Benzinga
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners
Roku vaulted 50% to become Ark Innovation's top holding. 
Via Investor's Business Daily
2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now
These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors. 
Via The Motley Fool
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on. 
Via InvestorPlace
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology. 
Via The Motley Fool
Verve Stock Soars On $250 Million Eli Lilly Deal
Eli Lilly now owns the opt-in rights to three more of Verve's cardiovascular drugs. 
Via Investor's Business Daily
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?
Some of the strategic shifts proposed by management are for the better. 
Via The Motley Fool
Why Beam Therapeutics Stock Is Getting Bought Today
Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY) agreed to acquire certain rights under Beam's  
Via Benzinga
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026 
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Scoops Up More Than $3M Worth Of SoFi Technologies Shares Amid Q3 Earnings Beat From Online Lender
Via Benzinga
Topics Earnings
5 Reasons Beam Therapeutics Remains a Risky Stock
Shares of the gene-editing biotech might not have hit rock bottom yet. 
Via The Motley Fool
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
From Beam Therapeutics
Via GlobeNewswire
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Beam Therapeutics Stock: Bear vs. Bull
This biotech has a few factors in its corner, but it also faces a difficult path. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback